Baylor Sammons Cancer Center, Dallas, TX, USA.
Blood. 2010 Oct 28;116(17):3119-20. doi: 10.1182/blood-2010-07-297523.
In this issue of Blood, Berentsen and coworkers describe a high response rate which is durable in some patients who receive combination fludarabine and rituximab for chronic cold agglutinin disease (CAD). If confirmed, this is a significant advance in therapy for a frequently difficult clinical problem.
在本期《Blood》杂志中，Berentsen 及其同事描述了接受氟达拉滨和利妥昔单抗联合治疗的慢性冷凝集素病（CAD）患者中，一些患者具有持久的高缓解率。如果得到证实，这将是对经常出现的棘手临床问题治疗的重大进展。
